Fever of Unknown Orgin Registry in Internal Medicine Unit and Infectious Disease Units
FUO
1 other identifier
observational
100
1 country
1
Brief Summary
This registry has the aim to collect epidemiological and clinical data of classical FUO cases in Italian Internal medicine Dept. and in Italian Infection diseases Dept.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 19, 2019
CompletedFirst Submitted
Initial submission to the registry
February 9, 2022
CompletedFirst Posted
Study publicly available on registry
February 24, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedFebruary 24, 2022
February 1, 2022
3.2 years
February 9, 2022
February 15, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
To describe FUO cases collected
To describe clinical evolution of classical FUO cases recording clinical data observed, diagnostic methods used.
6 moths
Interventions
not aplicable since it is a registry
Eligibility Criteria
All patients (in- or out-patients) with classical FUO hospitalised in Internal Medicine Dept. and in Infectious Diseases Dept.
You may qualify if:
- fever (temperature \> 38.3° C) found in several occasions of a duration exceeding 3, unable to make a diagnosis after a period of 3 days of hospitalization or after 3 out-patients visits in Internal Medicine Dept. or Infection Diseases Dept.
- signed informed consent
You may not qualify if:
- immunocompromised patients
- patients in treatment with steroidi (prednisone \> 0,5 mg/Kg/die per \> 4 weeks), anti-TNF, ciclofosfamide, tacrolimus, everolimus, sirolimus, azatioprina, ciclosporina, micofenolato, metotrexate
- neutropenic patients with less than 500 neutrofili/µL
- HIV positive patients
- nocosomial fever.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ASUI di Trieste
Trieste, Italy
Related Publications (1)
Luzzati R, Zerbato V, Attard L, Virgili G, Cilli A, Zanier A, Libanore M, Segala D, Tedesco A, Bortolotti ME, Pontali E, Feasi M, Re A, Giarretta I, Pomero F, Zagarri E, Concia E, Dentali F, Manfellotto D, Campanini M; FADOI-FUO Study Group. Fever of unknown origin (FUO) FADOI-SIMIT Italian registry: can demographics, comorbidities, and clinical variables predict the etiology of classic FUO?-a prospective Italian study. Intern Emerg Med. 2025 Nov;20(8):2331-2340. doi: 10.1007/s11739-025-04084-1. Epub 2025 Aug 19.
PMID: 40828443DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
ANDREA FONTANELLA
FADOI FOUNDATION
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2022
First Posted
February 24, 2022
Study Start
September 19, 2019
Primary Completion
December 1, 2022
Study Completion
December 1, 2022
Last Updated
February 24, 2022
Record last verified: 2022-02
Data Sharing
- IPD Sharing
- Will not share